MoFo BioMeter - Volume 2, Issue 1: February 2013


Phase 2 Deals Dominate Q4 and Full Year 2012 -

Morrison & Foerster is pleased to release the MoFo BioMeter for the fourth quarter of 2012 and for the full year of 2012.

The fourth quarter of 2012 saw an uptick in BioMeter value, with an average BioMeter value of approximately $26.8 million for license and collaboration agreements announced during the quarter, led by an increase in BioMeter values for Phase 2 transactions and a single high-value transaction for an approved product (BMS/Medicines Company). Transactions for Phase 2 and pre-clinical/ discovery products dominated the quarter, representing roughly 46% and 42% of transactions with reported stage of development. The total number of transactions with announced stage of development also increased slightly in the fourth quarter compared to the second and third quarters, but still lagged the first quarter. Overall, however, the dealmaking pace in Q4 remained slower than in prior years, reflecting the impact of industry consolidation and constrained development budgets.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.